Cost-effectiveness analyses have been under consideration as a way to help set prices for prescription drugs in the U.S. However, cost-effectiveness typically involves the use of the quality-adjusted life year (QALY) or similar metrics that have been shown to have a discriminatory impact on older adults and people with a disability. Further, addressing systemic health inequities continues as a key priority for many policymakers.
Given concerns about use of the QALY for other patient populations, the Alliance for Aging Research asked Charles River Associates to examine the implications for health disparities of adopting cost-effectiveness analysis, including Quality-Adjusted Life Years. The report examines the impact on Black and Latinx populations for two conditions, Alzheimer’s disease and colorectal cancer. Click here to read the full findings and report.
